首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症液體活檢

乳癌液態生物檢體市場規模、佔有率和成長分析（按循環生物標記、應用和地區分類）—產業預測，2026-2033年

市場調查報告書

商品編碼

1897987

乳癌液態生物檢體市場規模、佔有率和成長分析（按循環生物標記、應用和地區分類）—產業預測，2026-2033年

Breast Cancer Liquid Biopsy Market Size, Share, and Growth Analysis, By Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-Free Dna), By Application (Early Detection/Screening, Diagnosis), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，乳癌液態生物檢體市場規模將達到 5.117 億美元，到 2025 年將成長至 6.2785 億美元，到 2033 年將成長至 32.2562 億美元，在預測期（2026-2033 年）內複合成長率為 22.7%。

乳癌液態生物檢體市場正經歷顯著成長，這主要得益於人們對非侵入性診斷解決方案的認知度和接受度不斷提高。這項創新技術能夠識別腫瘤特異性基因突變、循環性腫瘤細胞和遊離DNA，為早期檢測、個人化治療策略和療效監測提供關鍵資訊。持續的技術進步有望提高這些診斷測試的敏感度和特異性，從而進一步推動市場擴張。此外，生物技術公司與醫療機構的合作以及對個人化治療日益成長的需求也推動了市場的發展。隨著醫學界擴大採用這種方法，乳癌液態生物檢體行業有望迎來顯著成長，並從根本上改變癌症的診斷和治療方式。

乳癌液態生物檢體市場促進因素

液態生物檢體技術的廣泛應用正在推動乳癌液態生物檢體市場的發展。與傳統的組織切片檢查相比，液態生物檢體具有顯著優勢，它能夠評估血液樣本中的循環性腫瘤細胞（CTC）、遊離DNA（cfDNA）以及各種生物標記。這種創新方法使醫療專業人員能夠根據患者的個人需求制定更明智的治療方案。此外，液態生物檢體還可以檢測抗藥性突變和微量殘存疾病，有助於制定個人化治療策略，在改善患者預後的同時降低醫療成本。隨著這些技術的日益普及，它們對患者照護的影響也日益顯著。

乳癌液態生物檢體市場的限制因素

乳癌液態生物檢體市場面臨諸多限制因素，主要原因在於這些先進診斷檢測的高成本。液態生物檢體技術的研究、開發和實施費用可能相當可觀，從而加重患者的經濟負擔。對於經濟資源有限或醫療資源匱乏的患者而言，這種情況尤其嚴峻，他們可能難以承擔檢測費用。此外，複雜的報銷政策和監管要求也可能阻礙液態生物檢體的廣泛應用，並限制其在不同醫療機構的普及。因此，解決這些成本相關的障礙並最佳化報銷機制對於提高乳癌患者普遍獲得液態生物檢體的機會至關重要。

乳癌液態生物檢體市場趨勢

乳癌液態生物檢體市場呈現顯著上升趨勢，這主要得益於人們對能夠早期發現和後續觀察乳癌的非侵入性診斷技術的日益關注。鑑於液態生物檢體具有許多優勢，例如出結果更快、患者不適感更低以及能夠捕捉腫瘤異質性，醫療服務提供者和患者正擴大尋求傳統組織切片檢查的替代方案。此外，檢測技術的進步和人們對個人化醫療日益成長的興趣也推動了市場成長。這一趨勢反映了腫瘤學領域在癌症診斷和治療方面轉向以患者為中心、更個人化的轉變。

F. Hoffmann-La Roche Ltd
Bio-Rad Laboratories Inc.
Illumina Inc.
Guardant Health Inc.
QIAGEN
Biocept Inc.
Thermo Fisher Scientific
Adaptive Biotechnologies
Myriad Genetics
Fluxion Biosciences Inc.
Biodesix
Exosome Diagnostics Inc.
Epic Sciences
PapGene
Pathway Genomics（OME Care）
Agena Bioscience
MDxHealth
Janssen Diagnostics
Abbott

結論與建議

簡介目錄

Product Code: SQMIG35J2098

Breast Cancer Liquid Biopsy Market size was valued at USD 511.7 Million in 2024 and is poised to grow from USD 627.85 Million in 2025 to USD 3225.62 Million by 2033, growing at a CAGR of 22.7% during the forecast period (2026-2033).

The breast cancer liquid biopsy market is witnessing remarkable growth fueled by increased awareness and acceptance of non-invasive diagnostic solutions. This innovative technology's capacity to identify tumor-specific genetic mutations, circulating tumor cells, and cell-free DNA offers vital insights for early detection, tailored treatment strategies, and monitoring responses to therapies. Ongoing advancements are set to enhance the sensitivity and specificity of these diagnostic tests, further propelling market expansion. Additionally, collaborations between biotech firms and healthcare providers, alongside a rising demand for personalized therapies, are contributing to the market's momentum. As the medical community increasingly adopts this approach, the breast cancer liquid biopsy industry is poised for substantial growth, fundamentally transforming cancer diagnostics and management practices.

Top-down and bottom-up approaches were used to estimate and validate the size of the Breast Cancer Liquid Biopsy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Breast Cancer Liquid Biopsy Market Segments Analysis

Global Breast Cancer Liquid Biopsy Market is segmented by circulating biomarkers, application, end users and region. Based on circulating biomarkers, the market is segmented into circulating tumor cells (CTCS), circulating cell-free DNA (CFDNA), extracellular vesicles (EVS) and other circulating biomarkers. Based on application, the market is segmented into early detection/screening, diagnosis, treatment selection and monitoring. Based on end users, the market is segmented into hospitals, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Breast Cancer Liquid Biopsy Market

The growing utilization of liquid biopsy methods significantly propels the breast cancer liquid biopsy market. Liquid biopsies offer a distinct advantage over conventional tissue biopsies by facilitating the evaluation of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and various biomarkers found in blood samples. This innovative approach empowers healthcare professionals to make more informed treatment decisions tailored to individual patient needs. Moreover, liquid biopsies can detect resistance mutations and minimal residual disease, contributing to personalized treatment strategies that enhance patient outcomes while simultaneously lowering healthcare expenses. As these techniques gain traction, their impact on patient care remains increasingly notable.

Restraints in the Breast Cancer Liquid Biopsy Market

The breast cancer liquid biopsy market faces notable constraints, primarily due to the high costs associated with these advanced diagnostic tests. The expenses related to the research, development, and implementation of liquid biopsy technologies can be substantial, leading to increased financial burdens on patients. This situation is particularly challenging for individuals with limited financial means or those living in areas with insufficient healthcare funding, as the tests may become prohibitively expensive. Furthermore, complexities surrounding reimbursement policies and regulatory requirements can impede the broader adoption of liquid biopsy, restricting its availability in various healthcare environments. Addressing these cost-related barriers and optimizing reimbursement frameworks is crucial for improving accessibility to liquid biopsy for breast cancer patients universally.

Market Trends of the Breast Cancer Liquid Biopsy Market

The Breast Cancer Liquid Biopsy market is experiencing a significant upward trend, driven by a rising emphasis on non-invasive diagnostic techniques that enable early detection and ongoing monitoring of breast cancer. Healthcare providers and patients are increasingly seeking alternatives to traditional tissue biopsies, given the advantages of liquid biopsies, which include faster results, reduced patient discomfort, and the ability to capture tumor heterogeneity. Additionally, advancements in detection technologies and a burgeoning focus on personalized medicine are propelling market growth. This trend reflects a broader shift in oncology towards more patient-centric and tailored approaches to cancer diagnosis and management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Case Study Analysis

Global Breast Cancer Liquid Biopsy Market Size by Circulating Biomarkers & CAGR (2026-2033)

Market Overview
Circulating Tumor Cells (CTCS)
Circulating Cell-Free DNA (CFDNA)
Extracellular Vesicles (EVS)
Other Circulating Biomarkers

Global Breast Cancer Liquid Biopsy Market Size by Application & CAGR (2026-2033)

Market Overview
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring

Global Breast Cancer Liquid Biopsy Market Size by End Users & CAGR (2026-2033)

Market Overview
Hospitals
Clinics
Others

Global Breast Cancer Liquid Biopsy Market Size & CAGR (2026-2033)

North America (Circulating Biomarkers, Application, End Users)
- USA
- Canada
Europe (Circulating Biomarkers, Application, End Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Circulating Biomarkers, Application, End Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Circulating Biomarkers, Application, End Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Circulating Biomarkers, Application, End Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocept Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptive Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fluxion Biosciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biodesix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exosome Diagnostics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Epic Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PapGene
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pathway Genomics (OME Care)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agena Bioscience
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MDxHealth
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments